US Lymphoma Therapeutics Market Analysis

US Lymphoma Therapeutic Market Executive Summary

US Lymphoma Therapeutics Market was valued at $2,914.80 Mn in 2023 and is predicted to grow at a CAGR of 6.30 % from 2023 to 2030, to $4,470.35 Mn by 2030.

Lymphoma is a cancer of the lymphatic system, categorized into Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL). HL is characterized by Reed-Sternberg cells, while NHL comprises various subtypes originating from lymphocytes. Symptoms include swollen lymph nodes, fever, weight loss, fatigue, and itchiness. Treatment options include chemotherapy, radiation therapy, immunotherapy, targeted therapy, and stem cell transplant, tailored based on the type, stage, and individual health status. Monitoring and follow-up care are crucial for managing treatment responses and side effects.

NHL (non-Hodgkin lymphoma) Makes up around 4% of all malignancies, NHL is one of the most prevalent cancers in the US. There will be about 80,620 people with NHL diagnoses in 2024 (44,590 men and 36,030 women). This applies to both kids and adults. It is anticipated that 20,140 people (11,780 men and 8,360 women) will pass away from the NHL.

For males and women respectively, the lifetime risk of having NHL is approximately 1 in 42 and 1 in 52. Between 2012 and 2021, the death rate fell by 2% per year, whereas NHL incidence rates have fallen by roughly 1% each year since 2015. Hodgkin lymphoma (HL), also adds to the total number of lymphomas in the US. There were 8,830 cases of HL in 2023. The key drivers of this industry include the rising prevalence of lymphoma, growing label extension, strong product pipeline, and rising geriatric population. The key drivers of this industry include the rising prevalence of lymphoma, growing label extension, strong product pipeline, and rising geriatric population. Restraints include patent expiry of blockbuster drugs, lack of awareness in emerging nations, adverse effects, and safety concerns.

The industry is primarily dominated by Bristol-Myers Squibb Company, Celgene Corporation, Merck & Co., Inc., and F. Hoffmann-La Roche Ltd, among others.

Market Dynamics

Market Growth Drivers

Rising Prevalence of Lymphoma: Lymphoma incidence rates are on the rise in the US, driving the need for effective therapeutic options to cater to the expanding patient base. This demand stimulates market growth as pharmaceutical companies strive to meet the increasing healthcare demands.

Growing Label Extension: Companies are actively broadening the indications of existing drugs to encompass various subtypes of lymphoma. This strategic expansion not only addresses the diverse needs of patients but also fosters market expansion by providing a wider array of treatment options within the US market.

Strong Product Pipeline: The US healthcare industry maintains a robust research and development pipeline focused on lymphoma therapies. Continuous innovation leads to the introduction of novel treatments, meeting unmet medical needs and fuelling market growth through the introduction of cutting-edge therapies.

Rising Geriatric Population: With the aging demographic in the US, there's a concurrent increase in lymphoma incidence among older individuals. This demographic shift drives demand for lymphoma treatments, given the higher susceptibility of the elderly population to the disease, thus contributing to market expansion.

Market Restraints

Patent Expiry of Blockbuster Drugs: The expiration of patents for key lymphoma medications poses a significant challenge in the US market. This event impacts revenue streams for pharmaceutical companies, leading to potential market disruptions and the introduction of generic alternatives, altering the competitive landscape.

Adverse Effects and Safety Concerns: Treatment-associated side effects pose significant challenges. While therapies may be effective, concerns regarding adverse effects can impact patient adherence and overall market uptake, requiring ongoing efforts to address safety concerns and improve treatment tolerability.

Regulatory Landscape and Reimbursement Scenario

The regulation of lymphoma therapy is greatly influenced by the Food and Drug Administration (FDA). It assesses novel medications, treatments, and equipment for efficacy and safety. A bispecific CD20-directed CD3 T-cell engager for recurrent or refractory follicular lymphoma, mosunetuzumab-axgb (Lunsumio), just received accelerated approval from the FDA. Thorough clinical trials and evidence-based evaluations are part of the approval procedure.

Insurance coverage and the cost of lymphoma therapies are decided by reimbursement frameworks. Distinct medicines have distinct reimbursement methods, such as CAR T-cell therapy and bispecific antibodies. Second-line diffuse large B-cell lymphoma (DLBCL) 2 treatment with axi-cel, a CAR T-cell therapy, has become more common. Payers, such as medicare and private insurers, negotiate reimbursement rates and coverage policies.

Competitive Landscape

Key Players

Here are some of the major key players in the US Lymphoma Therapeutic Market:

• Bristol-Myers Squibb Company
• Celgene Corporation
• Merck & Co., Inc.
• F. Hoffmann-La Roche Ltd.
• Seattle Genetics, Inc.
• Takeda Pharmaceutical Company Ltd.
• Johnson & Johnson
•  Eli Lilly and Company
• Abbott Laboratories
• Cipla Inc.
• AbbVie Inc.